Sention, formerly known as Nemogen, is a pharmaceutical development company focused on the discovery and development of drugs to treat memory impairment and other central nervous system disorders. buy Google Nexus One mugen battery

There are many opportunities for memory enhancement products. The market is large and growing rapidly due to the accelerating shift to an elderly population. An estimated 80% of people over 30 complain of some degree of memory loss. Memory impairment is a characteristic of normal aging as well as of many neurological disorders. Broadly speaking the patient population can be divided into four groups based on etiology: Age Associated Memory Impairment (AAMI), Alzheimer’s Disease, Stroke, and Traumatic Head Injury. Home Page - http://adultfrriendfinder.net/?p=3479 - Online Dating!

Sention has a pipeline of proprietary compounds which have shown efficacy in a variety of animal models of memory and cognition. The company initiated human clinical trials in 2002 with its lead compound, C105. The company is also actively working to develop lead compounds using its specialized genomics and behavioral models to treat other major central nervous system disorders.

The company, which is headquartered in Providence, Rhode Island, was founded in 1999 by a team of scientists and clinicians from Brown University and received early funding from David H. Smith and from the Economic Development Council of the State of Rhode Island. On March 5, 2001, the company closed on a $13 million venture funding lead by MPM Capital with Burrill and Company co-investing.